Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908

Infection and Immunity

Volumn 64, Issue 10, 1996, Pages 4172-4181

  Barry, Eileen M ^a   Gomez Duarte, Oscar ^a,d   Chatfield, Steven ^b   Rappuoli, Rino ^c   Pizza, Mariagrazia ^c   Losonsky, Genevieve ^a   Galen, James ^a   Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CHIRON VACCINES   (Italy)

^d MAX PLANCK INST FÜR BIOLOGIE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS TOXIN; TETANUS TOXIN; TYPHOID VACCINE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SALMONELLA TYPHI; TYPHOID FEVER; VACCINE PRODUCTION;

EID: 0029836634     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.10.4172-4181.1996     Document Type: Article

References (45)

1. Antoine, R., and C. Locht. 1990. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. 58:1518-1526.
2. Barbieri, J. T., D. Armellini, J. Molkentin, and R. Rappuoli. 1992. Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin. Infect. Immun. 60:5071-5077.
3. Boucher, P., H. Sato, and C. Locht. 1994. Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein. Infect. Immun. 62:449-456.
4. Chatfield, S. N., I. Charles, A. Makoff, M. Oxer, G. Dougan, D. Pickard, D. Slater, and N. Fairweather. 1992. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Bio/Technology 10:888-892.
5. Curtiss, R., S. Kelly, P. Gulig, and K. Nkayama. 1989. Selective delivery of antigens by recombinant bacteria. Curr. Top. Microbiol. Immunol. 14:35-49.
6. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenighini, R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosylating activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92:1644-1648.
7. Dougan, G., C. Hoemaeche, and D. Maskell. 1987. Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system. Parasitol. Immunol. 9:151-160.
8. Fairweather, N. F., S. N. Chatfield, A. J. Makoff, R. A. Strugnell, J. Bester, D. J. Maskell, and G. Dougan. 1990. Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier. Infect. Immun. 58:1323-1326.
9. Ferrante, A., M. Nandoskar, E. J. Bates, and D. H. B. Goh. 1987. Staphylococcus aureus-stimulated human mononuclear leukocyte-conditioned medium augments the basal and stimuli-induced neutrophil respiratory burst and degranulation. Immunology 60:431-438.
10. Fonts, T. R., G. K. Lewis, and D. M. Hone. 1995. Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine. Vaccine 13:561-569.
11. Galen, J. E., O. Gomez-Duarte, G. A. Losonsky, J. L. Halpern, C. S. Lauderbaugh, S. Kaintuck, M. K. Reymann, and M. M. Levine. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to foreign antigens. Submitted for publication.
12. Giron, J. A., J.-G. Xu, C. R. Gonzalez, D. Hone, J. B. Kaper, and M. M. Levine. 1995. Simultaneous and constitutive expression of CFA/I and CS3 colonization factors of enterotoxigenic Escherichia coli by ΔaroCΔaroD Salmonella typhi vaccine strain CVD 908. Vaccine 13:939-946.
13. Goldberg, A. L. 1972. Degradation of abnormal protein in E. coli. Proc. Natl. Acad. Sci. USA 69:422-426.
14. Gomez-Duarte, O. G., J. Galen, S. N. Chatfield, R. Rappuoli, L. Eidels, and M. M. Levine. 1995. Expression of fragment C of tetanus toxin fused to a C-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain. Vaccine 13:1596-1602.
15. Gonzalez, C., D. Hone, F. R. Noriega, C. O. Tacket, J. R. Davis, G. Losonsky, J. P. Nataro, S. Hoffman, A. Malik, E. Nardin, M. B. Szein, D. G. Heppner, T. R. Fouts, A. Isibasi, and M. M. Levine. 1994. Salmonella typhi strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction, safety and immunogenicity. J. Infect. Dis. 169:927-931.
16. Guzman, C. A., R. M. Brownlie, J. Kadurugamuwa, M. J. Walker, and K. N. Timmis. 1991. Antibody responses in the lungs of mice following oral immunization with Salmonella typhimurium aroA and invasive Escherichia coli strains expressing the filamentous hemagglutinin of Bordetella pertussis. Infect. Immun. 59:4391-4397.
17. Halpern, J. L., W. Habig, E. Neale, and S. Stibitz. 1990. Cloning and ex- pression of functional fragment C of tetanus toxin. Infect. Immun. 58:1004-1009.
18. Hewlett, E. L., K. T. Saver, G. A. Myers, J. L. Cowell, and R. L. Guerrant. 1983. Induction of a novel morphological response in Chinese hamster ovary cells. Infect. Immun. 40:1198-1203.
19. Hoiseth, S., and B. A. D. Stocker. 1981. Aromatic dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature (London) 291:238-239.
20. Hone, D. M., A. M. Harris, S. Chatfield, G. Dougan, and M. Levine. 1991. Construction of genetically-defined double am mutants of Salmonella typhi. Vaccine 9:810-816.
21. Hone, D. M., C. Tackett, A. Harris, B. Kay, G. Losonsky, and M. Levine. 1992. Evaluation in volunteers of a candidate live oral attenuated S. typhi vector vaccine. J. Clin. Invest. 90:1-9.
22. Jayarman, P. S., T. C. Peakman, S. J. W. Busby, R. V. Quincey, and J. A. Cole. 1987. Location and sequence of the promoter of the gene for the NADH-dependent nitrite reductase of Escherichia colt and its regulation by oxygen, the Fnr protein and nitrite. Mol. Biol. 196:781-788.
23. Jayaraman, P. S., J. A. Cole, and S. J. Busby. 1989. Mutational analysis of the nucleotide sequence at the FNR-dependent nirB promoter in Escherichia coli. Nucleic Acids Res. 17:135-145.
24. Katada, T., M. Tamura, and M. Ui. 1983. The A promoter of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein. Arch. Biochem. Biophys. 224:290-298.
25. Kenmer, J. G., K. J. Kim, P. G. Probst, C. R. Manclark, D. G. Burstyn, and J. L. Cowell. 1989. Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function. Hybridoma 8:37-51.
26. Khan, C., B. Villarreal-Ramos, R. Pierce, R. Demarco de Hormaeche, H. McNeill, T. Ali, S. Chatfield, A. Capron, G. Dougan, and C. Hormaeche. 1994. The construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella. J. Immunol. 153:5634-5642.
27. Kimura, M. 1990. Japanese clinical experiences with acellular pertussis vaccines. Dev. Biol. Stand. 73:5-9.
28. Levine, M. M., D. Hone, and G. Heppner, F. Noriega, and B. Sriwathana. 1990. Attenuated Salmonella as carriers for the expression of foreign antigens. Microecol. Ther. 19:23-32.
29. Locht, C., and J. M. Keith. 1986. Pertussis toxin gene: nucleotide sequence and genetic organization. Science 232:1258-1264.
30. Nencioni, L., M. Pizza, M. Bugnoli, M. T. De Magistris, A. Di Tommaso, F. Giovannoni, R. Manetti, I. Marsili, G. Matteucci, D. Nucci, R. Olivieri, P. Pileri, R. Presentini, L. Villa, H. Kreeftenberg, S. Silvestri, A. Tagliabue, and R. Rappuoli. 1990. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect. Immun. 58:1308-1315.
31. Orr, N., G. Robin, D. Cohen, R. Arnon, and G. H. Lowell. 1993. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2A and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect. Immun. 61:2390-2395.
32. Oxer, M. D., C. M. Bentley, J. G. Doyle, T. C. Peakman, I. G. Charles, and A. J. Makoff. 1991. High level heterologous expression in E. coli using the anaerobically-activated nirB promoter. Nucleic Acids Res. 19:2889-2892.
33. Pittman, M. 1984. The concept of pertussis as a toxin-mediated disease. Pediatr. Infect. Dis. J. 3:467-486.
34. Pizza, M., A. Covacci, A. Bartoloni, M. Perugini, L. Nencioni, M. T. De Magistris, L. Villa, D. Nucci, K. Manetti, M. Bugnoli, F. Giovannoni, R. Olivieri, J. T. Barbieri, H. Sato, and R. Rappuoli. 1989. Mutants of pertussis toxin suitable for vaccine development. Science 246:497-500.
35. Sato, H., A. Ito, and Y. Sato. 1984. Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect. Immun. 46:422-428.
36. Sato, H., and Y. Sato. 1990. Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect. Immun. 58:3369-3374.
37. Sato, H., Y. Sato, and I. Ohishi. 1991. Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies. Infect. Immun. 59:3832-3835.
38. Shahin, R., M. Leef, J. Eldridge, M. Hudson, and R. Gilley. 1995. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encap-salated in poly(DL-lactide-co-glycolide) microspheres. Infect. Immun. 63:1195-1200.
39. Strugnell, R., G. Dougan, S. Chatfield, I. Charles, N. Fairweather, J. Tite, J. L. Li, J. Beesley, and M. Roberts. 1992. Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis. Infect. Immun. 60:3994-41102.
40. Tacket, C., D. M. Hone, G. Losonsky, L. Guers, R. Edelman, and M. Levine. 1992. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 10:443-446.
41. Tamura, M., K. Nogimuri, S. Murai, M. Yajima, K. Ito, T. Katada, M. Ui, and S. Ishii. 1982. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 21:5516-5522.
42. Tamura, M., K. Nogimori, M. Yajima, K. Ase, and M. Ui. 1983. A role of the B oligomer moiety of islet activating protein, pertussis toxin, in development of the biological effects on infact cells. J. Biol. Chem. 258:6756-6761.
43. Trollfors, B., J. Taranger, T. Lagergard, L. Lind, V. Sundh, G. Zackrisson, C. U. Lowe, W. Blackwelder, and J. B. Robbins. 1995. A placebo-controlled trial of a pertussis toxoid vaccine. New Engl. J. Med. 333:1045-1050.
44. Walker, M. J., M. Rohde, K. N. Timmis, and C. A. Guzman. 1992. Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit. Infect. Immun. 60:4260-4268.
45. Weiss, A. A., and E. L. Hewlett. 1986. Virulence factors of Bordetella pertussis. Annu. Rev. Microbiol. 40:661-686.